NEW YORK (GenomeWeb News) - Agendia's CupPrint microarray service has acquired Medical Device registration at the Dutch Healthcare Inspectorate, the company said today.

 
Agendia received CE registration for MammaPrint in 2005.
 
CupPrint is a test for cancer of unknown primary patients.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.